Overview
On 27 June 2016, orphan designation (EU/3/16/1678) was granted by the European Commission to Kiadis Pharma Netherlands B.V., the Netherlands, for donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment (also called ATIR) for treatment in haematopoietic stem cell transplantation.
Please note that this product was withdrawn from the Union Register of orphan medicinal products in February 2022 on request of the Sponsor.
Key facts
Active substance |
Donor T lymphocytes depleted ex vivo of host alloreactive T cells using photodynamic treatment-
|
Intended use |
Treatment in haematopoietic stem cell transplantation
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/16/1678
|
Date of designation |
27/06/2016
|
Sponsor |
Kiadis Pharma Netherlands B.V.
Entrada 231-234 1114 AA Amsterdam-Duivendrecht The Netherlands Tel. +31 20 314 0250 Fax +31 20 314 0251 E-mail: regulatory.affairs@kiadis.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: